...
ymab-img

Y mAbs Therapeutics, Common Stock

YMAB

NSQ

$8.28

-$0.29

(-3.38%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$383.84M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.14M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.67
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.48 L
$20.9 H
$8.28

About Y mAbs Therapeutics, Common Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameYMABSectorS&P500
1-Week Return-12.2%-2.12%-3%
1-Month Return-21.44%-3.42%-0.73%
3-Month Return-39.69%-11.13%2.87%
6-Month Return-29.53%-5.74%7.17%
1-Year Return35.74%3.97%25.31%
3-Year Return-49.17%1.05%28.38%
5-Year Return-73.92%34.37%81.89%
10-Year Return-65.5%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-20.75M34.90M65.27M84.82M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":24.46,"profit":true},{"date":"2021-12-31","value":41.14,"profit":true},{"date":"2022-12-31","value":76.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue166.00K2.20M2.51M7.57M11.42M[{"date":"2019-12-31","value":1.45,"profit":true},{"date":"2020-12-31","value":19.3,"profit":true},{"date":"2021-12-31","value":22.02,"profit":true},{"date":"2022-12-31","value":66.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(166.00K)18.55M32.38M57.70M73.40M[{"date":"2019-12-31","value":-0.23,"profit":false},{"date":"2020-12-31","value":25.27,"profit":true},{"date":"2021-12-31","value":44.12,"profit":true},{"date":"2022-12-31","value":78.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin-89.38%92.80%88.41%86.54%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":96.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.27,"profit":true},{"date":"2023-12-31","value":93.26,"profit":true}]
Operating Expenses83.00M138.48M147.82M152.51M99.08M[{"date":"2019-12-31","value":54.42,"profit":true},{"date":"2020-12-31","value":90.8,"profit":true},{"date":"2021-12-31","value":96.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.96,"profit":true}]
Operating Income(83.00M)(119.94M)(115.43M)(94.81M)(25.67M)[{"date":"2019-12-31","value":-8300400000,"profit":false},{"date":"2020-12-31","value":-11993500000,"profit":false},{"date":"2021-12-31","value":-11543300000,"profit":false},{"date":"2022-12-31","value":-9481100000,"profit":false},{"date":"2023-12-31","value":-2567200000,"profit":false}]
Total Non-Operating Income/Expense3.95M1.20M58.31M(1.51M)9.52M[{"date":"2019-12-31","value":6.78,"profit":true},{"date":"2020-12-31","value":2.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.6,"profit":false},{"date":"2023-12-31","value":16.32,"profit":true}]
Pre-Tax Income(81.03M)(119.34M)(55.27M)(95.57M)(20.87M)[{"date":"2019-12-31","value":-8102800000,"profit":false},{"date":"2020-12-31","value":-11933700000,"profit":false},{"date":"2021-12-31","value":-5527500000,"profit":false},{"date":"2022-12-31","value":-9556800000,"profit":false},{"date":"2023-12-31","value":-2086600000,"profit":false}]
Income Taxes(2.14M)(994.00K)1.07M757.00K561.00K[{"date":"2019-12-31","value":-200.19,"profit":false},{"date":"2020-12-31","value":-92.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.75,"profit":true},{"date":"2023-12-31","value":52.43,"profit":true}]
Income After Taxes(78.89M)(118.34M)(56.34M)(96.33M)(21.43M)[{"date":"2019-12-31","value":-7888600000,"profit":false},{"date":"2020-12-31","value":-11834300000,"profit":false},{"date":"2021-12-31","value":-5634500000,"profit":false},{"date":"2022-12-31","value":-9632500000,"profit":false},{"date":"2023-12-31","value":-2142700000,"profit":false}]
Income From Continuous Operations(81.03M)(119.34M)(55.27M)(95.57M)(19.28M)[{"date":"2019-12-31","value":-8102800000,"profit":false},{"date":"2020-12-31","value":-11933700000,"profit":false},{"date":"2021-12-31","value":-5527500000,"profit":false},{"date":"2022-12-31","value":-9556800000,"profit":false},{"date":"2023-12-31","value":-1928200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(78.89M)(118.34M)(56.34M)(96.33M)(21.43M)[{"date":"2019-12-31","value":-7888600000,"profit":false},{"date":"2020-12-31","value":-11834300000,"profit":false},{"date":"2021-12-31","value":-5634500000,"profit":false},{"date":"2022-12-31","value":-9632500000,"profit":false},{"date":"2023-12-31","value":-2142700000,"profit":false}]
EPS (Diluted)(2.30)(2.97)(2.72)(2.18)(0.49)[{"date":"2019-12-31","value":-230,"profit":false},{"date":"2020-12-31","value":-297,"profit":false},{"date":"2021-12-31","value":-272,"profit":false},{"date":"2022-12-31","value":-218,"profit":false},{"date":"2023-12-31","value":-49,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

YMAB
Cash Ratio 2.69
Current Ratio 3.92
Quick Ratio 3.54

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

YMAB
ROA (LTM) -11.98%
ROE (LTM) -24.78%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

YMAB
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

YMAB
Trailing PE NM
Forward PE 119.05
P/S (TTM) 4.39
P/B 4.01
Price/FCF NM
EV/R 3.59
EV/Ebitda NM

FAQs

What is Y mAbs Therapeutics share price today?

Y mAbs Therapeutics (YMAB) share price today is $8.28

Can Indians buy Y mAbs Therapeutics shares?

Yes, Indians can buy shares of Y mAbs Therapeutics (YMAB) on Vested. To buy Y mAbs Therapeutics from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in YMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Y mAbs Therapeutics be purchased?

Yes, you can purchase fractional shares of Y mAbs Therapeutics (YMAB) via the Vested app. You can start investing in Y mAbs Therapeutics (YMAB) with a minimum investment of $1.

How to invest in Y mAbs Therapeutics shares from India?

You can invest in shares of Y mAbs Therapeutics (YMAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in YMAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Y mAbs Therapeutics shares
What is Y mAbs Therapeutics 52-week high and low stock price?

The 52-week high price of Y mAbs Therapeutics (YMAB) is $20.9. The 52-week low price of Y mAbs Therapeutics (YMAB) is $6.48.

What is Y mAbs Therapeutics price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Y mAbs Therapeutics (YMAB) is

What is Y mAbs Therapeutics price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Y mAbs Therapeutics (YMAB) is 4.01

What is Y mAbs Therapeutics dividend yield?

The dividend yield of Y mAbs Therapeutics (YMAB) is 0.00%

What is the Market Cap of Y mAbs Therapeutics?

The market capitalization of Y mAbs Therapeutics (YMAB) is $383.84M

What is Y mAbs Therapeutics’s stock symbol?

The stock symbol (or ticker) of Y mAbs Therapeutics is YMAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top